Lifetime cumulative exposure to low-density lipoprotein cholesterol (LDL-C) is among the key modifiable risk factors for atherosclerotic cardiovascular disease (ASCVD). Absolute LDL-C levels and the duration of exposure have been repeatedly demonstrated in observational and experimental studies as the driving forces behind the atherosclerotic process. This knowledge is the foundation for an effort to develop long-acting potent LDL-C–lowering drugs to achieve sustained reductions in ASCVD risk.
Leening MJG. Safety and Tolerability of Sustained Lipid-Lowering Therapy: Trial Data and Public Perception in a World Where Vaccines and Statins Are About to Collide. JAMA Cardiol. 2019;4(11):1075–1076. doi:10.1001/jamacardio.2019.3528
Customize your JAMA Network experience by selecting one or more topics from the list below.
Create a personal account or sign in to: